Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,215 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo group Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

NCT03743649
View directory record Official record
Conditions
Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 4:43 PM EDT
Terminated Not applicable Interventional

Assessing Neurocognitive Effects of Gluten Exposure

NCT01506349
View directory record Official record
Conditions
Celiac Disease, Neurobehavioral Manifestations
Interventions
gluten, Placebo
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 2, 2026, 4:43 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06252285
View directory record Official record
Conditions
RSV Immunisation
Interventions
RSVt Vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 21 Months
Enrollment
6,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Guntersville, Alabama • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

NCT03281876
View directory record Official record
Conditions
Respiratory Disorders
Interventions
NTHi Mcat investigational vaccine (GSK3277511A), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Palm Springs, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

NCT02942017
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome

NCT01452789
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
sublingual buprenorphine, oral morphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement

NCT00729690
View directory record Official record
Conditions
PAIN
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Asokumar Buvanendran
Other
Eligibility
55 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

NCT04927585
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 2, 2026, 4:43 PM EDT
Terminated Phase 3 Interventional Results available

Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

NCT01049217
View directory record Official record
Conditions
Neuropathy
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • North Hollywood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 2, 2026, 4:43 PM EDT
Not yet recruiting Early Phase 1 Interventional

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

NCT03474718
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Platelet-rich Plasma Left Side, Platelet-rich Plasma Right Side
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

NCT02147197
View directory record Official record
Conditions
Leiomyoma, Uterine Hemorrhage
Interventions
Ulipristal acetate (UPA), Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

NCT05501860
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Newport Beach, California • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 4 Interventional Results available

The Role of Orexin in Human Panic Disorder

NCT02593682
View directory record Official record
Conditions
Panic Disorder
Interventions
suvorexant, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

NCT01742208
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 2, 2026, 4:43 PM EDT
Recruiting Phase 3 Interventional

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
ICS-LABA, benralizumab, Placebo for Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

NCT04203797
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Rolling Hills Estates, California • Torrance, California • Westminster, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 3 Interventional

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

NCT06215820
View directory record Official record
Conditions
Acute Pain, Post Operative Pain, Pain
Interventions
MR-107A-02, Tramadol, Placebo, Bunionectomy
Drug · Procedure
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

NCT02219685
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 2, 2026, 4:43 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

NCT05750017
View directory record Official record
Conditions
Herpes Zoster, Vaccine-Preventable Diseases
Interventions
Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo
Biological · Drug
Lead sponsor
Beijing Luzhu Biotechnology Co., Ltd.
Other
Eligibility
50 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 3 Interventional

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

NCT00345618
View directory record Official record
Conditions
Embolism, Thrombosis
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 2, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional Results available

A Study of a Melatonin Receptor Agonist to Prevent Migraine

NCT00739024
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Investigational Test of a New Sleep Supplement

NCT03567343
View directory record Official record
Conditions
Sleep, Mood, Cognitive Performance
Interventions
Proprietary Spearmint Extract Blend, Control
Dietary Supplement · Other
Lead sponsor
University of Arizona
Other
Eligibility
22 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 2, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis

NCT00432835
View directory record Official record
Conditions
Gastroparesis
Interventions
Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
Device
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Sep 2, 2026, 4:43 PM EDT
Terminated Phase 1 Interventional

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

NCT01533376
View directory record Official record
Conditions
Sturge Weber Syndrome, Port-wine Mark
Interventions
Timolol, Preservative free artificial tear gel.
Drug
Lead sponsor
Wills Eye
Other
Eligibility
2 Years to 10 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 2, 2026, 4:43 PM EDT